The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

<p><strong>Background</strong></p> There is an ongoing global effort to design, manufacture, and clinically assess vaccines against SARS-CoV-2. Over the course of the ongoing pandemic a number of new SARS-CoV-2 virus isolates or variants of concern (VoC) have been identified...

Full description

Bibliographic Details
Main Authors:	Spencer, AJ, Morris, S, Ulaszewska, M, Powers, C, Kailath, R, Bissett, C, Truby, A, Thakur, N, Newman, J, Allen, ER, Rudiansyah, I, Liu, C, Dejnirattisai, W, Mongkolsapaya, J, Davies, H, Donnellan, FR, Pulido, D, Peacock, TP, Barclay, WS, Bright, H, Ren, K, Screaton, G, McTamney, P, Bailey, D, Gilbert, SC, Lambe, T
Format:	Journal article
Language:	English
Published:	Elsevier 2022

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

Similar Items